Tempest Therapeutics (TPST) Price & Analysis

Compare

1,262 Followers

TPST Stock Chart & Stats

$2.93

$0.02(2.27%)

At close: Jan 08 4:00 PM EST

$2.93

$0.02(2.27%)

Day’s Range― - ―

52-Week Range$3.00 - $13.65

Previous CloseN/A

Volume2.28M

Average Volume (3M)50.79K

Market Cap

$14.34M

Enterprise Value$20.24M

Total Cash (Recent Filing)$7.51M

Total Debt (Recent Filing)$8.40M

Price to Earnings (P/E)―

Beta2.09

Next Earnings

Apr 01, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.79

Shares Outstanding4,927,161

10 Day Avg. Volume57,939

30 Day Avg. Volume50,791

Financial Highlights & Ratios

PEG Ratio0.34

Price to Book (P/B)15.83

Price to Sales (P/S)0.00

P/FCF Ratio-9.05

Enterprise Value/Market Cap1.41

Enterprise Value/RevenueN/A

Enterprise Value/Gross Profit-152.20

Enterprise Value/Ebitda-0.57

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusHold

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Clinical DevelopmentTempest recently held a successful EOP2 meeting with the FDA, reaching a broad agreement on the Phase 3 study plan, including dose schedule and primary endpoint.

EarningsTempest posted EPS of ($3.16), which was better than both the analyst's estimate and the consensus estimate.

PartnershipsContinued support from Roche is seen as further validation of amezalpat's potential in changing the 1L HCC treatment landscape.

Bears Say

Funding NeedsTempest will still require a sizable cash infusion to fully support Phase 3 development, with management indicating it would cost approximately $100 million.

Market ConditionsThere is very deep frustration with Tempest's position due to the timing of data from Roche's MORPHEUS-Liver study and unprecedented conditions of the financial markets for healthcare funding.

Tempest Therapeutics News

Tempest Therapeutics files to sell 1.17M shares of common stock for holders

16:53 EST Tempest Therapeutics (TPST) files to sell 1.17M shares of common stock for holders Published first on...

10d ago

TPST

Tempest Therapeutics prices 1.17M shares at $3.63 in registered direct offering

Tempest Therapeutics (TPST) entered into a definitive agreement with a single healthcare-focused institutional investor for the purchase and...

24d ago

TPST

Tempest Therapeutics Secures $4.25M in Direct Offering

The latest update is out from Tempest Therapeutics ( ($TPST) ). On November 24, 2025, Tempest Therapeutics entered...

23d ago

TPST

Tempest Therpeutics trading resumes

09:51 EST Tempest Therpeutics trading resumes Published first on TheFly – the ultimate source for real-time, market-moving breaking...

1M ago

TPST

Tempest Therapeutics Announces New Leadership and Acquisition

Tempest Therapeutics ( ($TPST) ) has shared an announcement. Tempest Therapeutics, Inc. has entered into an Asset Purchase...

1M ago

TPST

Tempest Therpeutics trading halted, volatility trading pause

09:41 EST Tempest Therpeutics trading halted, volatility trading pause Published first on TheFly – the ultimate source for...

1M ago

TPST

Tempest announces acquisition of new dual-CAR T programs from Factor Bioscience

In a transaction designed to both expand its pipeline and extend its runway, Tempest Therapeutics (TPST) announced that...

1M ago

TPST

Tempest Therapeutics Reports Q3 2025 Financial Results

Tempest Therapeutics, Inc. ( ($TPST) ) has released its Q3 earnings. Here is a breakdown of the information...

1M ago

TPST

Tempest Therapeutics reports Q3 EPS (79c) vs ($5.32) last year

“We are continuing our strategic alternatives process with the goal of maximizing value for stockholders,” said Stephen Brady,...

1M ago

TPST

TPST Earnings this Week: How Will it Perform?

Tempest Therapeutics, Inc. (TPST) is scheduled to report 3rd quarter earnings on 11/05/2025. Regarding Q3 estimates, Wall Street...

2M ago

TPST

Tempest Therapeutics and Adagene’s Promising Advances in Liver Cancer Treatment

Tempest Therapeutics, Inc. (($TPST)), Adagene, Inc. (($ADAG)) announced an update on their ongoing clinical study. The clinical study...

2M ago

ADAG

TPST

Tempest Therapeutics’ Promising Phase 3 Trial for Liver Cancer Treatment

Tempest Therapeutics, Inc. (($TPST)) announced an update on their ongoing clinical study. Tempest Therapeutics, Inc. is conducting a...

2M ago

TPST

Six new option listings and option delistings on October 20th

New option listings for October 20th include Tradr 2X Long AUR Daily ETF (AURU), Tradr 2X Long CELH...

2M ago

CLPS

FLOT

Tempest Therapeutics Reports Q2 2025 Financial Results

Tempest Therapeutics, Inc. ( ($TPST) ) has released its Q2 earnings. Here is a breakdown of the information...

4M ago

TPST

TPST FAQ

What was Tempest Therapeutics’s price range in the past 12 months?

Tempest Therapeutics lowest stock price was $3.00 and its highest was $13.65 in the past 12 months.

What is Tempest Therapeutics’s market cap?

Tempest Therapeutics’s market cap is $14.34M.

When is Tempest Therapeutics’s upcoming earnings report date?

Tempest Therapeutics’s upcoming earnings report date is Apr 01, 2026 which is in 103 days.

How were Tempest Therapeutics’s earnings last quarter?

Tempest Therapeutics released its earnings results on Nov 05, 2025. The company reported -$0.79 earnings per share for the quarter, beating the consensus estimate of -$3.27 by $2.48.

Is Tempest Therapeutics overvalued?

According to Wall Street analysts Tempest Therapeutics’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Tempest Therapeutics pay dividends?

Tempest Therapeutics does not currently pay dividends.

What is Tempest Therapeutics’s EPS estimate?

Tempest Therapeutics’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Tempest Therapeutics have?

Tempest Therapeutics has 4,927,161 shares outstanding.

What happened to Tempest Therapeutics’s price movement after its last earnings report?

Tempest Therapeutics reported an EPS of -$0.79 in its last earnings report, beating expectations of -$3.27. Following the earnings report the stock price went up 9.101%.

Which hedge fund is a major shareholder of Tempest Therapeutics?

Currently, no hedge funds are holding shares in TPST

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Tempest Therapeutics

Tempest Therapeutics (TPST) is a clinical-stage biotechnology company focused on developing small molecule therapeutics for the treatment of cancer. The company is engaged in the research and development of novel therapies that harness the body's immune system to combat tumors. Tempest Therapeutics operates within the biotechnology sector, with its core products centered around advancing its pipeline of targeted oncology treatments.